Business
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company’s common stock, with a per share exerci
About this update from Candel Therapeutics, Inc.
[{"type":"image","alt":"Candel Therapeutics","displaySize":"","headline":null,"caption":"Candel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":137,"url":"https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_0g4zgCUCZX.eG19M3SXZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe","width":300,"height":137}},"lazy":false},{"type":"text","content":"NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company’s common stock, with a per share exercise price of $5.84.","length":518,"tagName":"p"},{"type":"text","content":"The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of the employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 36 equal monthly installments thereafter. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.","length":518,"tagName":"p"},{"type":"text","content":"The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.","length":287,"tagName":"p"},{"type":"text","content":"About Candel Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage mu...